[THE INVESTOR] Bridge Biotherapeutics announced on July 4 that it has received 11.5 billion won (US$ 10 million) investment from local venture capital firms including LB Investment and KB Investment.
Founded last year, Bridge Biotherapeutics is a local developer of biopharmaceuticals that focuses on commercializing compounds developed or discovered by a third party.
The company is currently working on BBT-401, anti-inflammatory agent discovered by a research team led by Sungkyunkwan University’s professor Park Seok-hee.
By Choi He-suk (
cheesuk@heraldcorp.com)
